利福平对中国健康男性志愿者中氟唑帕利药代动力学的影响
本研究在16名中国健康男性志愿者中评估利福平对氟唑帕利药代动力学的影响。单臂固定序列设计显示,利福平预处理后氟唑帕利的AUC0-∞和Cmax几何均值比分别为0.10(90%CI 0.095-0.115)和0.32(90%CI 0.281-0.365),暴露量显著降低。结论为氟唑帕利治疗期间应避免联用强CYP3A4诱导剂。
要点
- 氟唑帕利治疗期间应避免使用强CYP3A4诱导剂。
- 利福平预处理后单次氟唑帕利耐受良好,无严重不良事件。
核心结论
- 利福平预处理后氟唑帕利系统暴露量显著降低,提示应避免联用强CYP3A4诱导剂。
研究设计与样本
- 单中心、单臂、开放标签、固定序列研究,纳入16名中国健康男性受试者。
- 受试者先后在第1天单用氟唑帕利50 mg、第12天经利福平600 mg每日一次口服8天后再次使用氟唑帕利50 mg。
- 采用液相色谱-串联质谱法测定血药浓度,用Phoenix WinNonlin软件非房室法估算药代动力学参数。
主要发现
- 利福平预处理后氟唑帕利AUC0-∞和Cmax的几何均值比(90%CI)分别为0.10(0.095-0.115)和0.32(0.281-0.365)。
- 16例和15例受试者分别纳入单用氟唑帕利和利福平预处理后的药代动力学分析。
- 利福平多次给药后单次服用氟唑帕利耐受良好,未发生严重不良事件。
临床怎么用
- 临床使用氟唑帕利时应避免联用利福平等强CYP3A4诱导剂,以防暴露量显著下降影响疗效。
局限性
- 研究仅纳入健康中国男性志愿者,未涉及患者人群及女性。
- 样本量较小,为单臂固定序列设计,未设平行对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This clinical study was conducted to evaluate the impact of rifampicin on the pharmacokinetics of fuzuloparib. METHODS: In this single-centre, single-arm, open-label, fixed-sequence study, healthy male subjects took a single 50 mg dose of fuzuloparib on two separate occasions: the first was on Day 1 as monotherapy, and the second was on Day 12 after oral administration of rifampicin 600 mg once daily for 8 days. Series of blood samples were obtained before and after fuzuloparib administration at different time points: pre-dose, and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose. All samples were examined using liquid chromatography with tandem mass spectrometry. PK parameters were estimated by using a non-compartmental method with Phoenix WinNonlin software. Safety was assessed by monitoring for changes in vital signs and laboratory tests, physical examinations, and incidences of adverse events (AEs). RESULTS: A total of 16 Chinese male subjects were enrolled. Of these, 16 and 15 cases were evaluable for PK analysis following administration with fuzuloparib alone and pretreatment with rifampicin, respectively. Pretreatment with rifampicin resulted in a statistically significant reduction in the systemic exposure to fuzuloparib. The treatment ratio and 90% confidence intervals (CIs) for AUC0-∞ and Cmax were 0.10 (0.095-0.115) and 0.32 (0.281-0.365), respectively. A single administration of fuzuloparib after multiple oral dosing of rifampicin was well-tolerated, without severe AEs. CONCLUSION: The exposure of fuzuloparib was dramatically decreased when pretreated with rifampicin. Strong CYP3A4 inducers should be avoided during fuzuloparib treatment.
引用
- Zhang Q, Kai J, Zhai Y, et al. The impact of rifampicin on the pharmacokinetics of fuzuloparib in healthy Chinese male volunteers. Br J Clin Pharmacol. 2021. PMID: 34033139. doi:10.1111/bcp.14926
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。